Published in TB and Outbreaks Week, September 5th, 2000
The agreement allows Avant to further its clinical development of Ty800 in expanded Phase II studies, while Megan Health gains non-exclusive rights to use Avant's high-level expression system for human and non-human vaccines.
Fritz Casselman, Avant Immunotherapeutics, Inc., said: "We believe that Ty800 has strong potential to be an effective typhoid fever vaccine. If...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week